Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm

Business Wire May 19, 2022

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile May 19, 2022

AXSOME THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Axsome Therapeutics, Inc.

PR Newswire May 19, 2022

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors

Business Wire May 18, 2022

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile May 18, 2022

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Limited Shareholders

Newsfile May 18, 2022

Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry

PR Newswire May 18, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)

PR Newswire May 18, 2022

Shareholder Alert: Did You Purchase Shares of Axsome Therapeutics, Inc. (AXSM)? Robbins LLP Alerts Investors of Class Action Against Axsome Therapeutics, Inc.

Business Wire May 18, 2022

Axsome Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2022 to Discuss Your Rights - AXSM

Newsfile May 17, 2022

AXSOME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire May 17, 2022

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors

Business Wire May 17, 2022

SHAREHOLDER ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

PR Newswire May 17, 2022

AXSOME THERAPEUTICS, INC. (AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

Newsfile May 17, 2022

AXSM LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Axsome Therapeutics, Inc.

Newsfile May 17, 2022

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm

PR Newswire May 17, 2022

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Business Wire May 17, 2022

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Limited Shareholders

Newsfile May 16, 2022

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. With Losses of $500,000 to Contact the Firm

Business Wire May 16, 2022

AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Newsfile May 16, 2022